Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. / Urup, Thomas; Dahlrot, Rikke Hedegaard; Grunnet, Kirsten; Christensen, Ib Jarle; Michaelsen, Signe Regner; Toft, Anders; Larsen, Vibeke Andrée; Broholm, Helle; Kosteljanetz, Michael; Hansen, Steinbjørn; Poulsen, Hans Skovgaard; Lassen, Ulrik.
I: Acta Oncologica, Bind 55, Nr. 4, 2016, s. 418-22.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan
AU - Urup, Thomas
AU - Dahlrot, Rikke Hedegaard
AU - Grunnet, Kirsten
AU - Christensen, Ib Jarle
AU - Michaelsen, Signe Regner
AU - Toft, Anders
AU - Larsen, Vibeke Andrée
AU - Broholm, Helle
AU - Kosteljanetz, Michael
AU - Hansen, Steinbjørn
AU - Poulsen, Hans Skovgaard
AU - Lassen, Ulrik
PY - 2016
Y1 - 2016
N2 - BACKGROUND: Predictive markers and prognostic models are required in order to individualize treatment of recurrent glioblastoma (GBM) patients. Here, we sought to identify clinical factors able to predict response and survival in recurrent GBM patients treated with bevacizumab (BEV) and irinotecan.MATERIAL AND METHODS: A total of 219 recurrent GBM patients treated with BEV plus irinotecan according to a previously published treatment protocol were included in the initial population. Prognostic models were generated by means of multivariate logistic and Cox regression analysis.RESULTS: In multivariate analysis, corticosteroid use had a negative predictive impact on response at first evaluation (OR 0.45; 95% CI 0.22-0.93; p = 0.03) and at best response (OR 0.51; 95% CI 0.26-1.02; p = 0.056). Three significant (p < 0.05) prognostic factors associated with reduced progression-free survival and overall survival (OS) were identified. These factors were included in the final model for OS, namely corticosteroid use (HR 1.70; 95% CI 1.18-2.45; p = 0.004), neurocognitive deficit (HR 1.40; 95% CI 1.04-1.89; p = 0.03) and multifocal disease (HR 1.56; 95% CI 1.15-2.11; p < 0.0001). Based on these results a prognostic index able to calculate the probability for OS at 6 and 12 months for the individual patient was established. The predictive value of the model for OS was validated in a separate patient cohort of 85 patients.DISCUSSION AND CONCLUSION: A prognostic model for OS was established and validated. This model can be used by physicians to risk stratify the individual patient and together with the patient decide whether to initiate BEV relapse treatment.
AB - BACKGROUND: Predictive markers and prognostic models are required in order to individualize treatment of recurrent glioblastoma (GBM) patients. Here, we sought to identify clinical factors able to predict response and survival in recurrent GBM patients treated with bevacizumab (BEV) and irinotecan.MATERIAL AND METHODS: A total of 219 recurrent GBM patients treated with BEV plus irinotecan according to a previously published treatment protocol were included in the initial population. Prognostic models were generated by means of multivariate logistic and Cox regression analysis.RESULTS: In multivariate analysis, corticosteroid use had a negative predictive impact on response at first evaluation (OR 0.45; 95% CI 0.22-0.93; p = 0.03) and at best response (OR 0.51; 95% CI 0.26-1.02; p = 0.056). Three significant (p < 0.05) prognostic factors associated with reduced progression-free survival and overall survival (OS) were identified. These factors were included in the final model for OS, namely corticosteroid use (HR 1.70; 95% CI 1.18-2.45; p = 0.004), neurocognitive deficit (HR 1.40; 95% CI 1.04-1.89; p = 0.03) and multifocal disease (HR 1.56; 95% CI 1.15-2.11; p < 0.0001). Based on these results a prognostic index able to calculate the probability for OS at 6 and 12 months for the individual patient was established. The predictive value of the model for OS was validated in a separate patient cohort of 85 patients.DISCUSSION AND CONCLUSION: A prognostic model for OS was established and validated. This model can be used by physicians to risk stratify the individual patient and together with the patient decide whether to initiate BEV relapse treatment.
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.3109/0284186X.2015.1114679
DO - 10.3109/0284186X.2015.1114679
M3 - Journal article
C2 - 26828563
VL - 55
SP - 418
EP - 422
JO - Acta Oncologica
JF - Acta Oncologica
SN - 1100-1704
IS - 4
ER -
ID: 164817376